Citation Impact
Citing Papers
Cutting Edge: TIGIT Has T Cell-Intrinsic Inhibitory Functions
2011
Head‐to‐head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Findings of a phase IIIb, multinational, prospective, randomized study
2012
The Presumed Hyporesponsive Behavior of Rheumatoid Arthritis T Lymphocytes Can Be Attributed to Spontaneous Ex Vivo Apoptosis rather than Defects in T Cell Receptor Signaling
2009
CTLA4-Ig (abatacept) therapy modulates T cell effector functions in autoantibody-positive rheumatoid arthritis patients
2013
Autoimmune Th17 Cells Induced Synovial Stromal and Innate Lymphoid Cell Secretion of the Cytokine GM-CSF to Initiate and Augment Autoimmune Arthritis
2018 StandoutNobel
Synovitis in osteoarthritis: current understanding with therapeutic implications
2017 Standout
Infections requiring hospitalization in the abatacept clinical development program: an epidemiological assessment
2010
Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial
2014
Optimal approaches to data collection and analysis of potential immune mediated disorders in clinical trials of new vaccines
2013
Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study
2013
Clinicopathological significance of platelet-derived growth factor (PDGF)-B and vascular endothelial growth factor-A expression, PDGF receptor-β phosphorylation, and microvessel density in gastric cancer
2010
Methodology in conducting a systematic review of systematic reviews of healthcare interventions
2011 Standout
Control of Regulatory T Cells by Co-signal Molecules
2019 StandoutNobel
Probiotic supplementation improves inflammatory status in patients with rheumatoid arthritis
2013
Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis
2014
Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structu
2010
Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA
2010
Rheumatoid arthritis
2018 Standout
Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate
2010
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
2014 Standout
Rheumatoid arthritis
2009
Promising bone-related therapeutic targets for rheumatoid arthritis
2009
Rheumatoid arthritis
2016 Standout
Anti-citrullinated protein antibodies (ACPA) in early rheumatoid arthritis
2011
Synovial Tissue Inflammation Mediated by Autoimmune T Cells
2019 StandoutNobel
Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study
2010
Chronic inflammation in the etiology of disease across the life span
2019 Standout
SKG arthritis as a model for evaluating therapies in rheumatoid arthritis with special focus on bone changes
2012 StandoutNobel
Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial
2015
Safety of biological therapies following rituximab treatment in rheumatoid arthritis patients
2009
TFOS DEWS II Diagnostic Methodology report
2017 Standout
Abatacept in the treatment of patients with psoriatic arthritis: Results of a six‐month, multicenter, randomized, double‐blind, placebo‐controlled, phase II trial
2010
Timing the therapeutic window of opportunity in early rheumatoid arthritis: proposal for definitions of disease duration in clinical trials
2012
Therapies for Active Rheumatoid Arthritis after Methotrexate Failure
2013
Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19)
2020 Standout
The Risk of Infections with Biologic Therapies for Rheumatoid Arthritis
2009
Cell-autonomous and -non-autonomous roles of CTLA-4 in immune regulation
2011 StandoutNobel
How much does Disease Activity Score in 28 joints ESR and CRP calculations underestimate disease activity compared with the Simplified Disease Activity Index?
2014
Association of CD40 with rheumatoid arthritis confirmed in a large UK case-control study
2009
Systematic Review and Meta-Analysis of the Efficacy and Safety of Existing TNF Blocking Agents in Treatment of Rheumatoid Arthritis
2012
Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial
2011
Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults
2015 Standout
Biologics for rheumatoid arthritis: an overview of Cochrane reviews
2009
Incorporating the Treat-to-Target Concept in Rheumatoid Arthritis
2012
Use of abatacept in rheumatoid arthritis
2012
Graphical Tools for Network Meta-Analysis in STATA
2013 Standout
Avidin as a model for charge driven transport into cartilage and drug delivery for treating early stage post-traumatic osteoarthritis
2013 StandoutNobel
Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges
2015
The JAK/STAT signaling pathway: from bench to clinic
2021 Standout
Crohn's disease
2016 Standout
Chronic inflammatory diseases: Do immunological patterns drive the choice of biotechnology drugs? A critical review
2014
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
2018 Standout
Longterm Safety of Patients Receiving Rituximab in Rheumatoid Arthritis Clinical Trials
2010
Safety and Efficacy of the Selective Costimulation Modulator Abatacept in Patients with Rheumatoid Arthritis Receiving Background Methotrexate: A 5-year Extended Phase IIB Study
2009
Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment
2008
Periodontitis: from microbial immune subversion to systemic inflammation
2014 Standout
Abatacept: A Novel Treatment for Moderate‐to‐Severe Rheumatoid Arthritis
2007
Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis
2012
Molecular mechanisms of T cell co-stimulation and co-inhibition
2013 Standout
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
2011 Standout
Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors
2011 Standout
Type 1 diabetes
2013 Standout
Dysbiosis of the gut microbiota in disease
2015 Standout
Newer Biological Agents in Rheumatoid Arthritis
2010
Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
2016 Standout
Negative regulators of T‐cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections
2009 StandoutNobel
PTPN2 links colonic and joint inflammation in experimental autoimmune arthritis
2020 StandoutNobel
Abatacept therapy and safety management
2009
Rheumatoid arthritis
2010 Standout
Similar effects of disease‐modifying antirheumatic drugs, glucocorticoids, and biologic agents on radiographic progression in rheumatoid arthritis: Meta‐analysis of 70 randomized placebo‐controlled or drug‐controlled studies, including 112 comparisons
2010
Evidence for treating rheumatoid arthritis to target: results of a systematic literature search
2010
Tofacitinib versus Methotrexate in Rheumatoid Arthritis
2014
The pathogenesis of rheumatoid arthritis: new insights from old clinical data?
2012
Predicting arthritis outcomes--what can be learned from the Leiden Early Arthritis Clinic?
2010
A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview
2009
TREG-cell therapies for autoimmune rheumatic diseases
2014 StandoutNobel
Baricitinib in Patients with Refractory Rheumatoid Arthritis
2016
Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: A prospective, open-label, parallel-cohort, single-center study
2011
Treatment impact on estimated medical expenditure and job loss likelihood in rheumatoid arthritis: re-examining quality of life outcomes from a randomized placebo-controlled clinical trial with abatacept
2008
Inflammation (or synovitis)-driven osteoarthritis: an opportunity for personalizing prognosis and treatment?
2015
Abatacept for Rheumatoid Arthritis: A Cochrane Systematic Review
2010
Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment
2018
Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period
2014
Can we improve the performance and reporting of investigator-initiated clinical trials? Rheumatoid arthritis as an example
2014
Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study
2016
Preclinical disease and preventive strategies in IBD: perspectives, challenges and opportunities
2016
Macrophage Cytokines: Involvement in Immunity and Infectious Diseases
2014 Standout
Efficacy, pharmacodynamics, and safety of VX‐702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: Results of two randomized, double‐blind, placebo‐controlled clinical studies
2009
Pharmacological Properties and Molecular Mechanisms of Thymol: Prospects for Its Therapeutic Potential and Pharmaceutical Development
2017 Standout
Inflammation in obesity, diabetes, and related disorders
2022 Standout
Inflammatory bone loss: pathogenesis and therapeutic intervention
2012 Standout
Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction
2011
Interleukin‐6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: The role of acute‐phase reactants
2010
Fibroblast‐like synoviocytes: key effector cells in rheumatoid arthritis
2009 Standout
Nrf2 activation improves experimental rheumatoid arthritis
2023 StandoutNobel
T‐cell receptor signaling and the pathogenesis of autoimmune arthritis: insights from mouse and man
2012 StandoutNobel
Actinomyces and Related Organisms in Human Infections
2015 Standout
Clinically Important Changes in Short Form 36 Health Survey Scales for Use in Rheumatoid Arthritis Clinical Trials: The Impact of Low Responsiveness
2014
Psoriasis Pathogenesis and Treatment
2019 Standout
Anti-citrullinated protein antibodies (ACPA) in early rheumatoid arthritis
2012
Risk of Hospitalized Bacterial Infections Associated With Biologic Treatment Among US Veterans With Rheumatoid Arthritis
2014
Description of the Efficacy and Safety of Three New Biologics in the Treatment of Rheumatoid Arthritis
2010
Novel TNF antagonists for the treatment of rheumatoid arthritis
2009
The clinical utility of inhibiting CD28‐mediated costimulation
2009
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
2018 StandoutNobel
Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood
2016 StandoutNobel
Inflammation in dry eye associated with rheumatoid arthritis: Cytokine and in vivo confocal microscopy study
2013
Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis
2020
Explainable Artificial Intelligence (XAI): What we know and what is left to attain Trustworthy Artificial Intelligence
2023 Standout
A Randomized, Double‐Blind, Placebo‐Controlled, Twelve‐Week, Dose‐Ranging Study of Decernotinib, an Oral Selective JAK‐3 Inhibitor, as Monotherapy in Patients With Active Rheumatoid Arthritis
2014
2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host
2013 Standout
Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics
2017
VX‐509 (Decernotinib), an Oral Selective JAK‐3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis
2015
Impaired T cell receptor signaling and development of T cell–mediated autoimmune arthritis
2020 StandoutNobel
Generic quality-of-life assessment in rheumatoid arthritis.
2007
Works of J-C Becker being referenced
The Efficacy and Safety of Abatacept in SLE: Results of a 12-month Exploratory Study
2008
Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial)
2009
Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors
2009
Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate
2007
Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial
2007
Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy
2007
Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment
2006
Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate
2008
Role of receptor tyrosine kinases in gastric cancer: New targets for a selective therapy
2006
AN INTEGRATED SAFETY ANALYSIS OF ABATACEPT IN THE TREATMENT OF RHEUMATOID ARTHRITIS (RA) ACROSS PATIENT TYPES AND BACKGROUND THERAPIES
2006